The essentiality of chromium (Cr) has been questioned in the recent studies (Vincent, 2017) . Although some studies suggested that chromium supplementation decreases insulin levels and improves glucose disposal rates in obese individuals (Cefalu et al., 1999; Talavera, Reza, & Cerda, 2004) , in some other studies, Cr supplements to diabetic or healthy subjects did not clearly point out beneficial effects in glucose metabolism and diabetes (Bailey, 2014; Vincent, 2017) . In contrast to the results from clinical works in humans, studies with rodent models supplemented with Cr have unambiguously indicated certain roles of Cr as a pharmacologically active element in glucose tolerance factor (Vincent, 2017) . In this respect, supplementing chromium picolinate (CrPic) to the diet of obese rats has been shown to decrease plasma insulin, total cholesterol, and triacylglycerol concentrations as well as improved glucose disposal rates Wang, Zhang, Russell, Hulver, & Cefalu, 2006) . The effects of supplementing different doses and the combination of chromium histidinate (CrHis) and CrPic along with biotin in rats fed HFD have not been reported. Therefore, the aim of this study were to investigate the effects of supplementing different complexes of CrHis and CrPic supplementation along with biotin on the insulin sensitivity and also to evaluate the anti-obesity properties of these supplements through their action of mechanism by looking at the changes in biomarkers such as PPAR-γ, IRS-1, GLUTs, NF-κB proteins, metabolic parameters, and tissue histopathological changes in rats fed HFD.
| MATERIAL AND ME THODS

| Animals and diets
Sprague-Dawley male rats (n = 42, 8 weeks old) weighing 180-220 g were purchased from the Firat University Laboratory Animal Research Center (Elazig, Turkey). The animals were reared at the temperature of 22 ± 2°C, humidity of 55 ± 5%, and with a 12-h light-12-h dark cycle. All animal procedures were approved by the Animal Experimentation Ethics Committee of Firat University (Elazig, Turkey) (Bioethic Approval number 2014/17-164). All procedures involving rats were conducted in strict compliance with the relevant laws, the Animal Welfare Act, Public Health Services Policy, and guidelines established by the Institutional Animal Care and Use Committee of the Institute.
| Experimental design
After 1 week of adaptation period, the rats were divided according to BW, which was similar, into six equal groups containing seven rats each. The rats were fed either (a): a standard diet as control 
| Laboratory analyses
At the end of the experiment, all rats were killed by cervical dislocation. Blood samples were taken from rats from the tail vein in the morning, after overnight fasting, and the tissues from the liver and brain were removed and processed for biochemical and Western blot examination. Fat was trimmed off from the slow-twitch muscles (soleus and gastrocnemius deep portion). Visceral fat and liver weights were recorded. Initial body weight (BW), final BW, and feed intake were measured. Then, feed efficiency ratio (FER) was calculated as FER = [(total body weight gain × 100)/total feed intake].
Glucose, total cholesterol (TC), HDL cholesterol (HDL-C), LDL cholesterol (LDL-C), triglyceride (TG), free fatty acids (FFA), total protein (TP), total bilirubin (TBIL), blood urea nitrogen (BUN), and creatinine serum concentrations as well as alanine aminotransferase (ALT) and aspartate aminotransferase (AST) enzyme activities were measured by an automatic analyzer (Samsung LABGEO PT10; Samsung Electronics Co, Suwon, Korea). Repeatability and device/method precision of LABGEOPT10 was established according to the IVR-PT06 Guideline.
The concentration of serum leptin and insulin levels were measured with the rat leptin and insulin assay kit (Cayman Chemical Co., Ann
Arbor, MI, USA) by ELISA (Elx-800; Bio-Tek Instruments Inc., Vermont, USA). The interassay and intra-assay coefficients of variation were 4.6% and 6.3% and 3.8% and 5.5% for leptin and insulin, respectively.
Insulin resistance index was calculated by homeostasis model assessment of insulin resistance (HOMA-IR) as (fasting glucose mmol/L) × (fasting insulin mU/L)/22.5. Because this calculation is human based, basal concentrations are not the same in the rodents and should be re-estimated (strain differences) (van Dijk et al., 2013; Katz et al., 2000) . Therefore, HOMA-IR was calculated with a formula adapted to Matthews et al. (1985) . For Sprague-Dawley male rats, reference values were calculated using average fasting glucose (5.1 mmol/L) and plasma insulin (43.9 mU/L) concentrations from all group (42 rats) at the beginning of the study (day 0). The HOMA-IR score was calculated as the product of the fasting insulin level (mU/L) and the fasting glucose level (mmol/L), divided by 223.9 for rats.
The cutoff value to define insulin resistance was HOMA-IR ≥ 2.50.
Rats presenting HOMA-IR ≥ 2.50 were considered insulin-resistant.
Muscle malondialdehyde (MDA) concentrations were measured according to the previously described method (Akdemir et al., 2015) with a Shimadzu UV-vis SPD-10 AVP detector, a CTO-10 AS VP column and 30 mM KH2PO4 and methanol (82.5: 17.5, v/v, pH 3.6 ) at a flow rate of 1.2 ml/min. Column waste was monitored at 250 nm.
Feed, serum, and tissue chromium concentrations were determined as described previously (Akdemir et al., 2015) . For determination of Cr concentration, about 0.3 g feed, liver, and brain, as well as 0.5 ml serum samples were first digested with 5 ml concentrated nitric acid in a Microwave Digestion System (Berghof, Eningen, Germany) for 30 min. The specimens were subjected to graphite furnace atomic absorption spectrophotometer (AAS, Perkin-Elmer, Analyst 800, Norwalk, CT, USA).
| Western blot analyses
The protein levels of GLUT-1, GLUT-2, GLUT-3, GLUT-4, PPAR-γ, The blots were washed and incubated with horseradish peroxidaseconjugated goat antimouse IgG (Abcam). Specific binding was detected using diaminobenzidine and hydrogen peroxide as substrates.
Protein load was controlled using a monoclonal mouse antibody against β-actin antibody (Sigma, St. Louis, MO, USA). Protein levels were quantified densitometrically using an image analysis system (Image J; National Institute of Health, Bethesda, MD).
| Statistical analysis
The alteration among groups was analyzed using one-way analysis of variance (ANOVA) followed by the Tukey post hoc test (SAS Institute: SAS User's Guide: Statistics), and p < 0.05 was considered statistically significant. Data were stated as a mean and standard error of the mean.
| RE SULTS
| Body weight, visceral fat, and liver weights
Initial body weights, as planned, were similar among rat groups (p > 0.05, Table 2 ). Feeding rats a HFD compared with control resulted in an increase in final BW, FER, and visceral fat as well as the liver weights but a decrease in feed intake (p = 0.0001). However, 
| Serum metabolites
Feeding HFD to rats resulted in an increase in serum concentrations of glucose and insulin as well as HOMA-IR index (p < 0.05, Figure 1 ).
Adding each of the supplements, but particularly Cr complexes, to a HFD decreased the serum concentrations of glucose, insulin, and
Changes in serum metabolites upon feeding HFD supplemented with biotin, CrHis, CrPic, and CrHis + CrPic are shown in Table 3 .
Feeding HFD to rats resulted in an increase in serum concentra- 
| Oxidative stress indicator and Cr concentrations
As an indicator of oxidative stress, serum MDA concentrations increased with feeding HFD to rats (p = 0.0001; Table 4 
| Western blot analyses
Brain GLUT-1 and GLUT-3 levels showed similar responses to the treatments ( Figure 2 Panel a, b). The GLUT levels decreased in HFDfed rats compared to rats fed a control diet (100 vs. 40.99 and 30.37
for control, GLUT-1, and GLUT-3, respectively). Adding biotin and
CrPic to HFD resulted in increases in the levels; however, adding
CrHis and a combination of CrHis and CrPic further increased the levels with a similar magnitude (77.09 vs. 71.76 for GLUT-1 and 73.94
vs. 68.04 for GLUT-3, respectively).
Brain PPAR-γ levels decreased in rats fed HFD diets compared to rats fed a control diet (100 vs. 43.38, Figure 
86.96, respectively).
Feeding a HFD to rats resulted in a decrease in the brain IRS-1 levels ( The vitamin-mineral premix provides the following (per kg): all-trans-retinyl acetate, 1.8 mg; cholecalciferol, 0.025 mg; all-rac-atocopherol acetate, 12, 5 mg; menadione (menadione sodium bisulfate), 1.1 mg; riboflavin, 4.4 mg; thiamine (thiamine mononitrate), 1.1 mg; vitamin B + 6, 2.2 mg; niacin, 35 mg; Ca-pantothenate, 10 mg; vitamin B + 12, 0.02 mg; folic acid, 0.55 mg; d-biotin, 0.1 mg; manganese (from manganese oxide), 40 mg; iron (from iron sulfate), 12.5 mg; zinc (from zinc oxide), 25 mg; copper (from copper sulfate), 3.5 mg; iodine (from potassium iodide), 0.3 mg; selenium (from sodium selenite), 0.15 mg; choline chloride, 175 mg. the levels in a similar manner (87.75 vs. 102.85 for HFD + B + CrHis and HFD + B + CrHis + CrPic, respectively).
The levels of GLUT-2 and GLUT-4 in the liver are shown in 
| D ISCUSS I ON
Feeding HFD to rats for 12 weeks increased the final BW, visceral fats, and liver weights 19.38%, 226.59%, and 85.60%, respectively.
However, feed intake decreased with the same magnitude in all treatment groups. Decreased feed intake with feeding HFD could be due to an increase in serum leptin concentrations. In accord with the results of the present work, prolonged feeding with HFD has been shown to lead to obesity (Amin & Nagy, 2009; Buettner, Scholmerich, & Bollheimer, 2007; Tuzcu et al., 2011; Zhang, Lv, Li, Xu, & Chen, 2008) . Obesity is a medical condition leading to serious health problems including heart disease, type 2 diabetes, certain types of cancer, osteoarthritis, and sleep disorders (Slawson et al., 2013) . The treatment of obesity encloses the change of lifestyle including heart-friendly eating and increased physical activity, and the TA B L E 4 Serum MDA and tissue Cr concentrations in rats fed a HFD supplemented with biotin and chromium complexes use of authorities-approved weight-loss medicines and supplements.
Biotin and chromium should be considered as supplements in this respect.
Biotin supplemented HFD fed to rats decreased final BW, visceral fats, and liver weights. The results from biotin supplementation were expected due to the fact that biotin functions as glucose and lipid homeostasis through regulating the expression of genes needed in the regulation of intermediary metabolism (FernandezMejia, 2005) . Biotin has been found to stimulate the expression of insulin and pancreatic glucokinase, influencing insulin secretion (Romero-Navarro et al., 1999) , which were also the cases at the present work. Parallel to the results of the present work, biotin supplementation has been reported to ease the exacerbated hyperlipidemia (Báez-Saldaña et al., 2004; Dukusova & Krivoruchenko, 1972) . Marshall, Kliman, Washington, Mackin, & Weinland (1980) reported a negative correlation between biotin levels and total plasma lipids in healthy individuals. Zhang et al. (1996) also found that hyperglycemia is associated with biotin deficiencies in rats. In accord with the metabolic parameters measured at the present work, molecular parameters also supported the positive effect of biotin fed with HFD to rats for GLUT-1, GLUT-2, GLUT-3, GLUT-4, PPAR-γ, IRS-1, and NF-κB levels in tissues.
The three different Cr sources, namely, CrPic, CrHis, and the combination of CrPic and CrHis, were supplemented at the present work. CrPic is known as the lipophilic or slow-acting chromium complex, whereas CrHis is a hydrophilic or fast-acting chromium complex absorbed more quickly than that of CrPic. The combination of CrPic and CrHis was a mix at the ratio of 1:1 for CrPic:CrHis.
At the present work, supplementing CrHis along with biotin to HFD provided the best results yielding of the greatest levels of GLUT-1, GLUT-3, PPAR-γ, and IRS-1 but the lowest level of NF-κB in the brain tissues, the greatest levels of GLUT-1, GLUT-3, and PPAR-γ in the liver tissues, the lowest final body weights, visceral fat and liver weights, the lowest serum glucose, insulin, FFA, leptin, total cholesterol, LDL-cholesterol, HDL-cholesterol, and TG concentrations as well as lowest AST and ALT enzyme activities. Supplementing CrHis along with biotin to HFD also yielded second greatest levels of IRS-1 and second lowest levels of NF-κB in the liver tissues.
A wide range of metabolic dysfunctions characterized by insulin resistance, impaired glucose tolerance, obesity, intra-abdominal adiposity, hypertension, dyslipidemia, increased inflammatory markers, and oxidative stress is called cardiometabolic syndrome. Such conditions as obesity, hyperlipidemia, and diabetes play a crucial role in the development of atherosclerotic cardiovascular diseases, potential causes of mortality and morbidity (Abdelaal, le Roux, & Docherty, 2017; Slawson et al., 2013) . Chromium supplementation with CrPic, CrHis, or the combination (particularly CrHis alone) to HFD containing biotin resulted in an improvement in measured molecular parameters known to be characteristics to the conditions of cardiometabolic syndrome. Supplementing Cr with biotin to HFD also resulted in decreases in the final BW, visceral fats, and liver weights, promoting weight loss.
Rats fed HFD showed increased blood lipids and leptin concentrations which decreased by biotin and Cr supplementations, particularly CrHis. Circulating leptin concentrations increases in obesity. Therefore, the establishment of leptin resistance is considered as a major mechanism linking to the onset of obesity. Leptin is also crucial for the maintenance of glucose homeostasis and is considered as a potent insulin sensitizer (Yu, Park, Wang, Wang, & Unger, 2008) . In accord with other parameters measured at the present work, supplementing biotin but particularly with CrHis improves insulin resistance as well as obesity.
Disorders in insulin signaling through disruption in lipid and glucose metabolism cause insulin resistance, an important characteristic feature of type 2 diabetes (Cordero-Herrera, Martín, Bravo, Goya, & Ramos, 2013) . Glucose is transported to the muscle cells via the insulin-sensitive glucose transporter, GLUT4, and any disruption in the translocation of GLUT4 from an internal membrane pool to surface membranes may cause an impairment of insulin-stimulated glucose uptake, eventually leading to insulin resistance (Huang & Czech, 2007) . Chromium supplements attenuate insulin resistance by increasing the translocation of glucose causing depression in the expression (Shulman, 2000; White, 2002) .
On the other hand, serine/threonine phosphorylation of IRS-1 can also positively influence the insulin action via the residues which are specifically phosphorylated (Greene & Garofalo, 2002) . A number of There are three isoforms of PPAR receptors that have specific, but also overlapping target genes, namely, PPAR-α, PPAR-γ, and PPAR-β/δ. Activation of PPAR-γ is known to lead insulin sensitization and to enhance glucose metabolism as well as to regulate adipocyte differentiation and fatty acid storage (Tyagi, Gupta, Saini, Kaushal, & Sharma, 2011) . Decreased levels of PPAR-γ in the brain and liver tissues of the rats fed HFD were soared to levels near that of control with supplementing Cr to HFD, indicating the effects of chromium in improving insulin resistance as well as obesity. PPAR-γ activation is also known to inhibit the proliferation of malignant cells, including liposarcoma, breast adenocarcinoma, prostate carcinoma, colorectal carcinoma, non-small-cell lung carcinoma, pancreatic carcinoma, bladder cancer, gastric carcinoma, and glial tumors of the brain (Chattopadhyay et al., 2000; Rubin, Zhao, Kalus, & Simpson, 2000) .
Nuclear factor-κB (NF-κB) is involved in cellular responses to stimuli such as stress, cytokines, free radicals, ultraviolet irradiation, and bacterial or viral antigens. Therefore, the role of NF-kB in diseases such as inflammation, metabolic diseases including obesity, and cancer has been appreciated (Baker, Hayden, & Ghosh, 2011;  Ben-Neriah & Karin, 2011; Donath & Shoelson, 2011) . A relationship between the activation of the transcription factor nuclear factor-κB (NF-κB) and fatty acid-induced insulin resistance has been proposed (Kim et al., 2001) . were reported to have greater enzyme activities of ALT and AST (Kim, Ahn, Kim, & Jeong, 2016 ).
An increased level of serum MDA was observed in rats fed HFD, but biotin and chromium supplementations to the HFD decreased MDA levels. The results suggest that biotin and chromium have similar beneficial effects in attenuating oxidative stress caused by feeding a HFD. In accord with the results of the present work, it has been known that overproduction of reactive oxygen species (ROS) occurs in obesity caused by feeding a HFD (Furukawa et al., 2004; Zhang, Dong, Ren, Driscoll, & Culver, 2005) , and the resulting oxidative damage leads to diabetes and related complications (West, 2000) .
Improved parameters observed with Cr supplementation were due to the increased serum and tissue Cr concentrations, resulting in an improvement of insulin resistance as well as obesity. Elevated
Cr concentrations of serum and the tissues in rats of the present work supplemented with Cr, CrHis in particular, were similar to those reported in different animal species with various doses (Anderson, Bryden, Polansky, & Richards, 1989; Wang & Xu, 2004; Wang et al., 2012; Zha, Wang, Xu, & Gu, 2007) . Similar to the results from the present work, the apparent superiority of CrHis over CrPic was also supported by other studies in diabetic rats fed a HFD (Sahin et al., 2012; Tuzcu et al., 2011 ).
In conclusion, our results demonstrate that biotin supplementation alone or with chromium complexes, CrHis at particular, to a HFD pose to be a potential therapeutic feature for the treatment of insulin resistance and in the prevention of diabetes and its secondary complications.
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